The drug induced a 100 percent reduction in symptomatic infection, as well as decreased overall infection rates by about half. The findings are based on preliminary analysis of a clinical trial run by the National Institute of Allergy and Infectious Disease in which 400 participants were exposed to a household member with COVID-19.
The treatment is a combination of casirivimab and imdevimab, two antibodies that fight against COVID-19. The FDA granted it emergency use authorization Nov. 21, allowing the antibody cocktail, which is administered intravenously as a one-time treatment, to be used in COVID-19 patients age 12 and over who weigh at least 88 pounds and have a high risk of their case becoming severe.
The U.S. on Jan. 12 agreed to buy up to 1.25 million doses of the antibody drug in a deal worth up to $2.6 billion.
Regenron’s announcement comes five days after Eli Lilly made a similar announcement about its antibody drug bamlanivimab, saying preliminary analysis showed it significantly reduced the risk of contracting symptomatic COVID-19 in residents and staff of long-term care facilities.
More articles on pharmacy:
CivicaRx to build drug manufacturing facility in Virginia
CVS says it’s completed first-round COVID-19 shots for skilled nursing facilities
White House: States can’t buy COVID-19 vaccines directly from drugmakers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
